Search Results 8091-8100 of 34364 for oral
... Oral and throat cancer, Adenocarcinoma, Laryngeal cancer, Carotid body tumor, Tongue base cancer, Mouth tumor, Salivary gland cancer, Parotid cancer ...
Are able to swallow and retain oral tablets. Exclusion Criteria: Patients with any of the following sarcoma histologic subtypes will not be eligible for ...
Patients with known EGFR mutations (except exon 20 insertion), BRAF mutations (V600) or ALK or ROS1 translocations that can be treated with oral tyrosine kinase ...
Safety of endoscopic ultrasound-guided tissue acquisition with uninterrupted direct oral anticoagulation in a swine model. Endosc Int Open. 2023 Apr; 11(4): ...
DEAR MAYO CLINIC: How effective is cold cap therapy in preventing hair loss in people undergoing chemotherapy treatments? Are there any risks?
... (Oral Anti-Platelet) agents. In addition to exploring ED treatment patterns and success of both ischemic and bleeding risk stratification prior to definition ...
... oral, inhaled or systemically injected steroids with duration >14 days, adrenocorticotropic hormone, verapamil). Past systemic immunosuppression medicine or ...
inability to take oral medication;; malabsorption syndromes;; requirement for intravenous (IV) alimentation. Any active bleeding excluding hemorrhoidal or gum ...
Participants must be able to swallow and retain oral medications. Oxygen saturation > 92% on room air or up to 2 L/min supplemental oxygen by nasal cannula ...
2024. Kincaid CM, Sharma AN, Sargent B, Gradus-Pizlo I, Dineen EH, Mesinkovska NA. Evaluation of Pericardial Effusions in Alopecia Patients on Low-Dose Oral ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your donation powers the future of medicine and helps save lives.